Human Genome Sciences (HGSI) Gets FDA Okay for Phase 3 LymphoStat-B Study
More News related to HGSI
- Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BIO CEO Investor Conference
- Benlysta Will Garner Sales of More Than $500 Million in 2018 in the Systemic Lupus Erythematosus Drug Market
- Human Genome Sciences Names Scott Habig Vice President, Sales
- RBC Capital Initiates Coverage on Human Genome Sciences (HGSI) with an Outperform
- Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
Human Genome Sciences, Inc. (Nasdaq: HGSI) received a Special Protocol Assessment from the FDA, agreeing to the Company's Phase 3 clinical development program for LymphoStat-B in patients with active systemic lupus erythematosus.
CEO Thomas Watkins said, "We expect to initiate Phase 3 trials of LymphoStat-B before the end of 2006, and we look forward to moving ahead with site activation and patient enrollment."
Related Categories
FDAStocks Mentioned
+1.30Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
